OBJECTIVES: To characterize the contemporary use of oral-targeted therapies (ie, sunitinib, sorafenib) among patients with renal cell carcinoma (RCC) and to assess the factors associated with short-term and sequential treatment. METHODS: We used an administrative claims database of privately insured patients to evaluate oral-targeted therapy use among patients with RCC from 2006 to 2007. After identifying patients with RCC who had received sunitinib and/or sorafenib, we determined the prevalence of patients treated with short-term and/or sequential therapy. We performed bivariate and multivariate analyses to estimate the associations between the patient characteristics and receipt of short-term and/or sequential treatment regimens. RESULTS: We identified 938 patients with RCC who had initially been treated with sunitinib (n = 554) or sorafenib (n = 384). In this group, 36% and 23% of patients had received short-term or sequential therapy, respectively. Most patients (61%) who had received sequential therapy had undergone short-term treatment with ≥1 drugs, with second-line sorafenib more likely to be given as short-term therapy than sunitinib (63% vs 34%, P < .001). Short-term therapy was more common in female patients (odds ratio 1.53, 95% confidence interval 1.12-2.09) and patients in the Southern United States (odds ratio 1.71, 95% confidence interval 1.05-2.80). Sequential therapy was more common among patients receiving sorafenib first (odds ratio 2.30, 95% confidence interval 1.64-3.21). CONCLUSIONS: Short-term and sequential oral targeted therapy use was relatively prevalent among patients with RCC. For patients treated with sunitinib and sorafenib, the patterns of short-term use varied by the sequence of medications, suggesting differences in the effectiveness or tolerability of each regimen. These findings highlight the need for future studies to characterize the "real-world" clinical outcomes and economic effect associated with these treatment courses.
OBJECTIVES: To characterize the contemporary use of oral-targeted therapies (ie, sunitinib, sorafenib) among patients with renal cell carcinoma (RCC) and to assess the factors associated with short-term and sequential treatment. METHODS: We used an administrative claims database of privately insured patients to evaluate oral-targeted therapy use among patients with RCC from 2006 to 2007. After identifying patients with RCC who had received sunitinib and/or sorafenib, we determined the prevalence of patients treated with short-term and/or sequential therapy. We performed bivariate and multivariate analyses to estimate the associations between the patient characteristics and receipt of short-term and/or sequential treatment regimens. RESULTS: We identified 938 patients with RCC who had initially been treated with sunitinib (n = 554) or sorafenib (n = 384). In this group, 36% and 23% of patients had received short-term or sequential therapy, respectively. Most patients (61%) who had received sequential therapy had undergone short-term treatment with ≥1 drugs, with second-line sorafenib more likely to be given as short-term therapy than sunitinib (63% vs 34%, P < .001). Short-term therapy was more common in female patients (odds ratio 1.53, 95% confidence interval 1.12-2.09) and patients in the Southern United States (odds ratio 1.71, 95% confidence interval 1.05-2.80). Sequential therapy was more common among patients receiving sorafenib first (odds ratio 2.30, 95% confidence interval 1.64-3.21). CONCLUSIONS: Short-term and sequential oral targeted therapy use was relatively prevalent among patients with RCC. For patients treated with sunitinib and sorafenib, the patterns of short-term use varied by the sequence of medications, suggesting differences in the effectiveness or tolerability of each regimen. These findings highlight the need for future studies to characterize the "real-world" clinical outcomes and economic effect associated with these treatment courses.
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Robert C Kane; Ann T Farrell; Haleh Saber; Shenghui Tang; Gene Williams; Josephine M Jee; Chengyi Liang; Brian Booth; Nallaperumal Chidambaram; David Morse; Rajeshwari Sridhara; Patricia Garvey; Robert Justice; Richard Pazdur Journal: Clin Cancer Res Date: 2006-12-15 Impact factor: 12.531
Authors: M P Sablin; S Negrier; A Ravaud; S Oudard; C Balleyguier; J Gautier; C Celier; J Medioni; B Escudier Journal: J Urol Date: 2009-05-17 Impact factor: 7.450
Authors: Christian Eichelberg; Roman Heuer; Felix K Chun; Kristin Hinrichs; Mario Zacharias; Hartwig Huland; Hans Heinzer Journal: Eur Urol Date: 2008-08-08 Impact factor: 20.096
Authors: D Y Heng; M J Mackenzie; U N Vaishampayan; G A Bjarnason; J J Knox; M H Tan; L Wood; Y Wang; C Kollmannsberger; S North; F Donskov; B I Rini; T K Choueiri Journal: Ann Oncol Date: 2011-11-05 Impact factor: 32.976
Authors: Eduard Vrdoljak; Lajos Géczi; Jozef Mardiak; Tudor-Eliade Ciuleanu; Sophie Leyman; Ke Zhang; Peter Sajben; Laszlo Torday Journal: Pathol Oncol Res Date: 2015-01-04 Impact factor: 3.201